GALT
GALT
NASDAQ · Biotechnology

Galectin Therapeutics Inc

$2.68
-0.12 (-4.29%)
As of Mar 29, 10:36 PM ET ·
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +383.6% upside
Low Target $9.51
Average Target $12.96
High Target $17.52
Current Price $2.68
Current
$2.68
Target
$12.96
$9.51 $12.96 avg $17.52
Scenario Analysis
Bear Case
$9.51
254.9%
Low target
Base Case
$12.96
+383.6%
Avg target
Bull Case
$17.52
+553.7%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$7.13
-62.4% from high
52-Week Low
$1.12
+139.3% from low
Target vs 52W High
$12.96
+81.8% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +19.8%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.0%
GILD
Gilead Sciences Inc
Strong Buy 38 79% $362.68 +158.5%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.1%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -13.0%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -29.7%